top of page

What RMAT Designation Actually Means for a Gene Therapy

13 minutes ago
3 min read

If you follow gene therapy news, you will see the letters RMAT in many headlines. This month alone, a sickle cell stem cell therapy, a heart gene therapy and a bladder cancer gene therapy were all described as holding Regenerative Medicine Advanced Therapy (RMAT) designation. Here is what the designation is, what it does, and what it does not mean.


Illustration of a winding pathway with gene therapy vials and DNA strands travelling past milestone markers

Where RMAT came from

RMAT was created by the 21st Century Cures Act, a US law passed in December 2016. The FDA's Center for Biologics Evaluation and Research (CBER), which oversees cell and gene therapies, began granting it in 2017.


Who can get it

A therapy qualifies for RMAT if it meets three conditions:

  • It is a regenerative medicine therapy: a cell therapy, a therapeutic tissue-engineering product, a human cell or tissue product, or a combination of these. The FDA has said that gene therapies, including genetically modified cells, can qualify.

  • It is meant to treat, modify, reverse or cure a serious or life-threatening disease or condition.

  • Preliminary clinical evidence shows it may address an unmet medical need for that condition.

The third point is important. RMAT requires early data from people, not only from animal studies. That is one difference from Fast Track, which can be granted on the strength of non-clinical data.


What it gives a developer

RMAT includes all the benefits of the FDA's Fast Track and Breakthrough Therapy designations:

  • Early and frequent meetings with the FDA to discuss the development plan, including how to design trials that could support approval.

  • Eligibility for priority review, which shortens the FDA's review goal from about ten months to about six.

  • Eligibility for accelerated approval, which allows approval based on an early sign of benefit, called a surrogate endpoint, that is reasonably likely to predict a real clinical benefit. Confirmatory studies are then needed after approval.

  • Rolling review, which lets a company submit parts of its application as they are ready.


Flowchart showing preliminary clinical evidence leading to RMAT designation, which branches into early FDA meetings, priority review, accelerated approval and rolling review

What RMAT does not mean

RMAT is not an approval, and it does not mean the FDA has decided a therapy works or is safe. Many therapies with RMAT designation never reach approval. The designation is a signal that early results look promising enough to justify closer FDA involvement.


RMAT in this week's news

Earlier this year, Grace Science's GS-100 for NGLY1 deficiency also received RMAT designation.


The bottom line

RMAT is a special FDA designation for cell and gene therapies that treat serious diseases and show early promise in people. It brings more FDA guidance and opens faster review paths, but it is not an approval. When you see "RMAT" in a headline, read it as "promising and on a faster track," not "proven."



Keep exploring with Gene Tech Times

As an Amazon Associate, Gene Tech Times earns from qualifying purchases.

— T.N., Gene Tech Times

Comments


Subscribe for News

bottom of page